Celator Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CELATOR PHARMS, and when can generic versions of CELATOR PHARMS drugs launch?
CELATOR PHARMS has one approved drug.
There are nine US patents protecting CELATOR PHARMS drugs.
There are one hundred and nineteen patent family members on CELATOR PHARMS drugs in twenty-five countries and twenty-three supplementary protection certificates in fifteen countries.
Summary for Celator Pharms
| International Patents: | 119 |
| US Patents: | 9 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Celator Pharms
International Patents for Celator Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3572071 | See Plans and Pricing |
| Taiwan | I329025 | See Plans and Pricing |
| Canada | 2852777 | See Plans and Pricing |
| Cyprus | 1119631 | See Plans and Pricing |
| World Intellectual Property Organization (WIPO) | 03028696 | See Plans and Pricing |
| South Korea | 102024836 | See Plans and Pricing |
| European Patent Office | 3300601 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Celator Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2768484 | 132019000000144 | Italy | See Plans and Pricing | PRODUCT NAME: DAUNORUBICINA E CITARABINA(VYXEOS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1308, 20180827 |
| 1744764 | C201830057 | Spain | See Plans and Pricing | PRODUCT NAME: DAUNORUBICINA + CITARABINA; NATIONAL AUTHORISATION NUMBER: EU/1/18/1308; DATE OF AUTHORISATION: 20180823; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1308; DATE OF FIRST AUTHORISATION IN EEA: 20180823 |
| 2768484 | 53/2019 | Austria | See Plans and Pricing | PRODUCT NAME: KOMBINATION VON DAUNORUBICIN UND CYTARABIN; REGISTRATION NO/DATE: EU/1/18/1308 (MITTEILUNG) 20180827 |
| 1744764 | 2018C/045 | Belgium | See Plans and Pricing | PRODUCT NAME: VYXEOS (DAUNORUBICINE/CYTARABINE); AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180823 |
| 2768484 | 1990053-9 | Sweden | See Plans and Pricing | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REG. NO/DATE: EU/1/18/1308 20180827 |
| 1744764 | SPC/GB18/045 | United Kingdom | See Plans and Pricing | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTERED: UK EU/1/18/1308/001-003 20180827; UK PLGB 31626/0004 20180827 |
| 1744764 | 122018000134 | Germany | See Plans and Pricing | PRODUCT NAME: ZUSAMMENSETZUNG AUS KOMPONENTE 1 DAUNORUBICIN MIT KOMPONENTE 2 CYTARABIN; REGISTRATION NO/DATE: EU/1/18/1308 20180823 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
